-
Products are supplied strictly for laboratory and scientific research — not for human or veterinary use.
MOTS-c is a mitochondrial-derived peptide that has attracted interest in metabolism, cellular stress and healthy-aging research. Unlike many peptides encoded in nuclear DNA, MOTS-c is associated with mitochondrial genetic information, making it an unusual research target.
Preclinical studies have examined relationships among MOTS-c, cellular energy sensing, glucose metabolism, exercise responses and stress adaptation. These findings help scientists form hypotheses; they do not establish that an experimental MOTS-c product improves weight, performance or longevity in people.
Human research remains limited compared with the evidence required for an approved medicine. Observational associations and small exploratory studies cannot determine broad safety, effective use or long-term outcomes.
MOTS-c is not an FDA-approved drug. FDA’s 2026 advisory-committee process considered MOTS-c-related bulk substances in the context of compounding, but committee discussion or voting does not equal drug approval.
Both appear in metabolic-research conversations, but their proposed biology is different. GLP-1 receptor agonists have approved medicines backed by large clinical programs; experimental MOTS-c research should not be placed on the same evidentiary level.
No. They involve different biological pathways.
No.
No. Research-use products are not intended for human or veterinary use.
Research catalog CTA: Explore MOTS-c specifications for qualified laboratory research. Not for human or veterinary use.
Authoritative source: FDA July 2026 advisory-committee page and briefing materials: Authoritative source
